Cushing's Disease

Endocrinology
8
Pipeline Programs
2
Companies
3
Clinical Trials
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 2 programs with unclassified modality

On Market (5)

Approved therapies currently available

Corcept Therapeutics
KORLYMApproved
mifepristone
Corcept Therapeutics
Progestin Antagonist [EPC]oral2012
U
MIFEPREXApproved
mifepristone
Unknown Company
oral2000
U
MIFEPRISTONEApproved
mifepristone
Unknown Company
Progestin Antagonist [EPC]oral2019
Recordati
SIGNIFORApproved
pasireotide
Recordati
Somatostatin Analog [EPC]subcutaneous2012
Recordati
SIGNIFOR LAR KITApproved
pasireotide
Recordati
intramuscular2014

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
2 programs
2
1
MifepristonePhase 31 trial
mifepristonePhase 31 trial
Active Trials
NCT01371565Completed4Est. Sep 2012
NCT01925092Withdrawn0
Recordati
RecordatiFrance - Saint-Victor
1 program
1
PasireotidePhase 4Peptide1 trial
Active Trials
NCT01794793Completed337Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RecordatiPasireotide
Corcept Therapeuticsmifepristone
Corcept TherapeuticsMifepristone

Clinical Trials (3)

Total enrollment: 341 patients across 3 trials

NCT01794793RecordatiPasireotide

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Start: Jun 2013Est. completion: Jul 2023337 patients
Phase 4Completed
NCT01925092Corcept Therapeuticsmifepristone

Mifepristone in Children With Refractory Cushing's Disease

Start: Aug 20130
Phase 3Withdrawn
NCT01371565Corcept TherapeuticsMifepristone

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Start: Nov 2010Est. completion: Sep 20124 patients
Phase 3Completed

Related Jobs in Endocrinology

Research Associate I/II - Biology

Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr

Associate Director, Clinical Operations

Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr

Associate Director/Director, Regulatory Affairs

Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr

Medical Science Liaison (rare diseases)

Amgen
Poland - Lódz
1mo ago

Senior/Executive Director, Analytical Development

Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr

Senior Clinical Scientist - Job ID: 1845

Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Acromegaly(67)Growth Hormone Deficiency(39)Growth Hormone Disorder(37)Hypogonadism(21)Secondary Hyperparathyroidism(13)Hypoparathyroidism(12)Thyroid Eye Disease(11)Adult Growth Hormone Deficiency(10)Hypothyroidism(9)Cushing's Syndrome(9)